GenEdit

About GenEdit

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

```xml <problem> Current CRISPR-Cas9 gene editing therapies face challenges in safe and efficient delivery, limiting their accessibility and effectiveness for treating a wide range of genetic diseases. The lack of targeted delivery mechanisms hinders the ability of these therapies to reach the intended cells and tissues, reducing their therapeutic potential. </problem> <solution> GenEdit is developing the NanoGalaxy® delivery platform to improve the delivery of CRISPR-Cas9 gene editing therapies. This platform aims to enhance the safety, specificity, and efficiency of gene editing by enabling targeted delivery of therapeutic payloads to specific cells and tissues within the body. By overcoming delivery limitations, NanoGalaxy® seeks to expand the range of treatable diseases and improve patient outcomes. The platform is designed to facilitate the development of innovative genetic medicines that can effectively edit out disease and rewrite patient health. </solution> <features> - Targeted delivery of CRISPR-Cas9 components to specific cells and tissues - Enhanced safety profile compared to traditional delivery methods - Improved efficiency of gene editing within target cells - Versatile platform applicable to a wide range of genetic diseases </features> <target_audience> The primary target audience includes researchers and pharmaceutical companies developing CRISPR-Cas9 based gene editing therapies for genetic diseases. </target_audience> ```

What does GenEdit do?

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

Where is GenEdit located?

GenEdit is based in South San Francisco, United States.

When was GenEdit founded?

GenEdit was founded in 2016.

How much funding has GenEdit raised?

GenEdit has raised 24000000.

Location
South San Francisco, United States
Founded
2016
Funding
24000000
Employees
55 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

GenEdit

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

GenEdit utilizes the NanoGalaxy® delivery platform to enhance the safe and efficient delivery of CRISPR-Cas9 gene editing therapies for genetic diseases. This technology addresses the challenge of limited access to effective genetic medicines, enabling broader patient treatment options.

genedit.com3K+
cb
Crunchbase
Founded 2016South San Francisco, United States

Funding

$

Estimated Funding

$20M+

Team (50+)

No team information available.

Company Description

Problem

Current CRISPR-Cas9 gene editing therapies face challenges in safe and efficient delivery, limiting their accessibility and effectiveness for treating a wide range of genetic diseases. The lack of targeted delivery mechanisms hinders the ability of these therapies to reach the intended cells and tissues, reducing their therapeutic potential.

Solution

GenEdit is developing the NanoGalaxy® delivery platform to improve the delivery of CRISPR-Cas9 gene editing therapies. This platform aims to enhance the safety, specificity, and efficiency of gene editing by enabling targeted delivery of therapeutic payloads to specific cells and tissues within the body. By overcoming delivery limitations, NanoGalaxy® seeks to expand the range of treatable diseases and improve patient outcomes. The platform is designed to facilitate the development of innovative genetic medicines that can effectively edit out disease and rewrite patient health.

Features

Targeted delivery of CRISPR-Cas9 components to specific cells and tissues

Enhanced safety profile compared to traditional delivery methods

Improved efficiency of gene editing within target cells

Versatile platform applicable to a wide range of genetic diseases

Target Audience

The primary target audience includes researchers and pharmaceutical companies developing CRISPR-Cas9 based gene editing therapies for genetic diseases.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.